Lilly advances obesity and inflammation pipeline with new Phase 1 trials, Phase 2 updates

Eli Lilly's clinicaltrials.gov records were updated across ten studies this week, ranging from ongoing Phase 2 combination trials to newly posted Phase 1 programs.

• Lilly's Phase 2 study of eltrekibart (LY3041658) combined with mirikizumab in ulcerative colitis is active and not recruiting. The study's main purpose is to determine the safety and efficacy of eltrekibart and mirikizumab in adult participants with moderately to severely active ulcerative colitis. The trial spans 207 sites in 21 countries and primary completion was listed as August 3, 2026.
• A Phase 2 study testing macupatide (LY3532226) and eloralintide (LY3841136), alone and combined, in adults with obesity or overweight and type 2 diabetes is also active and not recruiting. The purpose is to investigate weight reduction with macupatide and eloralintide, alone or in combination, in adult participants with obesity or overweight and with type 2 diabetes. Enrollment is estimated at 200 participants, with primary completion expected in March 2027.
• A Phase 1 study of LY5625575, also called ZMG-3003936, is recruiting. The main purpose is to evaluate the safety and tolerability of LY5625575 in healthy participants, including Japanese and Chinese participants, and in participants with high levels of C-reactive protein. Enrollment is estimated at 204 participants.
• A related but not yet recruiting Phase 1 study of LY5625573, also known as VTX3232, will test the same single and multiple ascending doses in healthy participants, including Japanese and Chinese populations, and in those with elevated CRP, a study designed to learn if LY5625573 is safe and how well it is tolerated in healthy participants, including Japanese and Chinese participants, and in participants with high levels of a marker for inflammation. Enrollment is estimated at 96 participants.
• Lilly's master protocol for Phase 1 trials of multiple amyloid-targeting therapies in Alzheimer's disease is recruiting. The protocol supports multiple studies looking at safety and tolerability of different drugs in healthy participants and participants with Alzheimer's disease, and whether they remove amyloid plaque in the brain. Enrollment is estimated at 179 participants across 18 sites in the United States, China, and Japan.
• A Phase 1 study of LY4329090 in participants with obesity or overweight is recruiting. The main purpose is to assess how well LY4329090 is tolerated and what side effects may occur in healthy participants with obesity or overweight. Enrollment is estimated at 184 participants.
• A Phase 1 study of eloralintide (LY3841136) examining its effect on a combined oral contraceptive in women with obesity or overweight is recruiting. The main purpose is to evaluate how eloralintide affects the way the body processes an oral contraceptive in female participants with obesity or overweight. Enrollment is estimated at 34 participants.
• A not yet recruiting Phase 1 study of [¹⁴C]-LY4515100 will examine the drug's absorption, metabolism, and excretion in healthy male participants. Enrollment is estimated at 16 participants, with the study to run at a single Fortrea site in Madison, Wisconsin.
• A Phase 1 study of LY4268989 (MORF-057) is active and not recruiting. The purpose is to identify if two different tablets of LY4268989 work similarly in healthy participants given different meals. Enrollment is estimated at 50 participants.